Cumberland Pharmaceu (CPIX) 4.62 $CPIX Cumberla
Post# of 273258
Posted On: 09/03/2016 1:17:55 AM
Cumberland Pharmaceu (CPIX) 4.62 $CPIX
Cumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient Support
PR Newswire - Tue Aug 23, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing Ethyol® (amifostine) for injection to U.S. wholesalers today. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 02, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2016 financial results with Net Revenues of $7.4 million and Adjusted Earnings of $0.7 million or $0.04 per share.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals Announces Caroline Young To Join Its Board Of Directors
PR Newswire - Fri Jun 10, 7:00AM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is pleased to announce the addition of Caroline Young to its Board of Directors. Caroline is the prior President of the Nashville Health Care Council and founding Executive Director of the Tennessee Biotechnology Association.
CPIX: 4.62 (+0.04)
Cumberland reports 1Q loss
Automated Insights - Tue May 10, 4:36PM CDT
NASHVILLE, Tenn. (AP) _ Cumberland Pharmaceuticals Inc. (CPIX) on Tuesday reported a first-quarter loss of $253,000, after reporting a profit in the same period a year earlier.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2016 financial results with Net Revenues of $7.7 million and Adjusted Earnings of $0.3 million or $0.02 per share.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals and Clinigen Group enter into exclusive U.S. commercialization agreement for oncology support drug Ethyol®
PR Newswire - Tue May 10, 6:00AM CDT
Cumberland Pharmaceuticals Inc. ('Cumberland', NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinigen Group plc ('Clinigen', AIM: CLIN), the global pharmaceutical and services company, have signed an exclusive agreement to commercialize the oncology support drug, Ethyol® (amifostine), in the U.S. This is the first product Clinigen has licensed to Cumberland under the strategic alliance entered into late last year.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals To Announce First Quarter 2016 Financial Results
PR Newswire - Tue May 03, 3:15PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2016 financial results after the market closes on Tuesday, May 10, 2016. A conference call and live Internet webcast will be held on Tuesday, May 10, 2016, at 4:30 p.m. Eastern Time to discuss the results.
CPIX: 4.62 (+0.04)
Caldolor® Launched For The Treatment Of Pain And Fever In Children
PR Newswire - Thu Mar 24, 6:30AM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) a specialty pharmaceutical company, today announced the launch of Caldolor® (ibuprofen) injection for pediatric patients. This launch follows the U.S. Food and Drug Administration (FDA) approval of Caldolor for the treatment of pain and fever in children six months of age and older. Caldolor is an injectable form of ibuprofen designed primarily for hospitalized patients who are not able to tolerate their pain and fever medications orally. It is the first and only injectable non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of pain and fever in pediatric patients.
CPIX: 4.62 (+0.04)
Vaprisol Dose Comparison Published Supporting Its Efficacy, Safety And Pharmacokinetics
PR Newswire - Wed Feb 10, 7:30AM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of an open label multicenter study adding to the growing body of literature that supports Vaprisol® (conivaptan) Injection. The study evaluated both 20 and 40 mg/day doses of conivaptan in hyponatremic patients. The new publication is currently available as open access articles in the journal Drug Design, Development and Therapy.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals AND Piramal Critical Care announces co-promotion agreement throughout the US for Caldolor and Vaprisol
M2 - Tue Jan 26, 4:53AM CST
Specialist pharmaceutical company Cumberland Pharmaceuticals (NasdaqGS:CPIX) said on Monday that it has officially entered into a co-promotion agreement throughout the US for two of its branded hospital products, Caldolor and Vaprisol, with Piramal Critical Care.
CPIX: 4.62 (+0.04)
Drug Overdose Global Clinical Trials Review, H2, 2015 - Key Vendors: BTG Plc, Cumberland Pharmaceuticals, Inc. & Altasciences Company Inc - Research and Markets
BusinessWire - Tue Jan 19, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/pgfk79/drug_overdose) has announced the addition of the "Drug Overdose Global Clinical Trials Review, H2, 2015" report to their offering.
CPIX: 4.62 (+0.04)
Drug Overdose Global Clinical Trials Review, H2, 2015 - Key Vendors: BTG Plc, Cumberland Pharmaceuticals, Inc. & Altasciences Company Inc
M2 - Mon Jan 18, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/7rp5wx/drug_overdose) has announced the addition of the "Drug Overdose Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Drug Overdose Global Clinical Trials Review, H2, 2015" provides an overview of Drug Overdose clinical trials scenario. This report provides top line data relating to the clinical trials on Drug Overdose. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - BTG Plc - ZonMw - Smerud Medical Research International AS - Cumberland Pharmaceuticals, Inc. - AS The Norwegian Ether Factory - Altasciences Company Inc For more information visit http://www.researchandmarkets.com/research/7r...g_overdose
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals Presentation Now Available for On-Demand Viewing
CNW Group - Mon Dec 07, 7:30AM CST
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
CPIX: 4.62 (+0.04)
Equities on the Move - Research on Select Bancorp, Cumberland Pharmaceuticals, Howard Bancorp and Atlantic Coast Financial
ACCESSWIRE - Wed Dec 02, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / December 2, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Select Bancorp Inc (NASDAQ: SLCT), Cumberland Pharmaceuticals Inc (NASDAQ: CPIX), Howard Bancorp Inc (NASDAQ: HBMD) and Atlantic Coast Financial Corp (NASDAQ: ACFC). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HBMD: 12.82 (+0.16), CPIX: 4.62 (+0.04), SLCT: 8.04 (+0.01), ACFC: 6.70 (+0.03)
NYSE, Nasdaq and OTC Companies to Present Online to Investors on December 3
CNW Group - Tue Dec 01, 2:07PM CST
VirtualInvestorsConferences.com host CEOs and senior executives: live questions answered during online roadshow and in virtual trade booths
SAN: 4.56 (+0.04), CPG: 15.38 (+0.24), CPIX: 4.62 (+0.04), IMUC: 0.12 (-0.01)
Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 3
PR Newswire - Mon Nov 30, 8:05AM CST
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
CPIX: 4.62 (+0.04)
Caldolor® Launched In Australia For Treatment Of Pain And Fever
PR Newswire - Mon Nov 23, 3:05PM CST
Cumberland Pharmaceuticals (NASDAQ: CPIX) announced today the launch of Caldolor® in Australia. Caldolor is an intravenous formulation of ibuprofen, approved by Therapeutic Goods Administration (TGA) in Australia as a new injectable, non-narcotic treatment for pain and reduction of fever in adults. It is designed primarily for patients in the hospital setting, who cannot tolerate oral medications. Caldolor is distributed in Australia by Seqirus(TM), a part of the CSL Group, under license from Cumberland Pharmaceuticals Inc. who developed and registered the product in the United States.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals Begins U.S. Shipments Of Ethyol® (amifostine) For Oncology Patient Support
PR Newswire - Tue Aug 23, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on the development of innovative treatments for underserved patient populations, will begin distributing Ethyol® (amifostine) for injection to U.S. wholesalers today. Ethyol is an FDA approved cytoprotective drug indicated to reduce the incidence of xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer. It also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 02, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced second quarter 2016 financial results with Net Revenues of $7.4 million and Adjusted Earnings of $0.7 million or $0.04 per share.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals Announces Caroline Young To Join Its Board Of Directors
PR Newswire - Fri Jun 10, 7:00AM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is pleased to announce the addition of Caroline Young to its Board of Directors. Caroline is the prior President of the Nashville Health Care Council and founding Executive Director of the Tennessee Biotechnology Association.
CPIX: 4.62 (+0.04)
Cumberland reports 1Q loss
Automated Insights - Tue May 10, 4:36PM CDT
NASHVILLE, Tenn. (AP) _ Cumberland Pharmaceuticals Inc. (CPIX) on Tuesday reported a first-quarter loss of $253,000, after reporting a profit in the same period a year earlier.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 3:05PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced first quarter 2016 financial results with Net Revenues of $7.7 million and Adjusted Earnings of $0.3 million or $0.02 per share.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals and Clinigen Group enter into exclusive U.S. commercialization agreement for oncology support drug Ethyol®
PR Newswire - Tue May 10, 6:00AM CDT
Cumberland Pharmaceuticals Inc. ('Cumberland', NASDAQ: CPIX), a U.S. specialty pharmaceutical company and Clinigen Group plc ('Clinigen', AIM: CLIN), the global pharmaceutical and services company, have signed an exclusive agreement to commercialize the oncology support drug, Ethyol® (amifostine), in the U.S. This is the first product Clinigen has licensed to Cumberland under the strategic alliance entered into late last year.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals To Announce First Quarter 2016 Financial Results
PR Newswire - Tue May 03, 3:15PM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2016 financial results after the market closes on Tuesday, May 10, 2016. A conference call and live Internet webcast will be held on Tuesday, May 10, 2016, at 4:30 p.m. Eastern Time to discuss the results.
CPIX: 4.62 (+0.04)
Caldolor® Launched For The Treatment Of Pain And Fever In Children
PR Newswire - Thu Mar 24, 6:30AM CDT
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) a specialty pharmaceutical company, today announced the launch of Caldolor® (ibuprofen) injection for pediatric patients. This launch follows the U.S. Food and Drug Administration (FDA) approval of Caldolor for the treatment of pain and fever in children six months of age and older. Caldolor is an injectable form of ibuprofen designed primarily for hospitalized patients who are not able to tolerate their pain and fever medications orally. It is the first and only injectable non-steroidal anti-inflammatory drug (NSAID) approved for the treatment of pain and fever in pediatric patients.
CPIX: 4.62 (+0.04)
Vaprisol Dose Comparison Published Supporting Its Efficacy, Safety And Pharmacokinetics
PR Newswire - Wed Feb 10, 7:30AM CST
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced the publication of an open label multicenter study adding to the growing body of literature that supports Vaprisol® (conivaptan) Injection. The study evaluated both 20 and 40 mg/day doses of conivaptan in hyponatremic patients. The new publication is currently available as open access articles in the journal Drug Design, Development and Therapy.
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals AND Piramal Critical Care announces co-promotion agreement throughout the US for Caldolor and Vaprisol
M2 - Tue Jan 26, 4:53AM CST
Specialist pharmaceutical company Cumberland Pharmaceuticals (NasdaqGS:CPIX) said on Monday that it has officially entered into a co-promotion agreement throughout the US for two of its branded hospital products, Caldolor and Vaprisol, with Piramal Critical Care.
CPIX: 4.62 (+0.04)
Drug Overdose Global Clinical Trials Review, H2, 2015 - Key Vendors: BTG Plc, Cumberland Pharmaceuticals, Inc. & Altasciences Company Inc - Research and Markets
BusinessWire - Tue Jan 19, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/pgfk79/drug_overdose) has announced the addition of the "Drug Overdose Global Clinical Trials Review, H2, 2015" report to their offering.
CPIX: 4.62 (+0.04)
Drug Overdose Global Clinical Trials Review, H2, 2015 - Key Vendors: BTG Plc, Cumberland Pharmaceuticals, Inc. & Altasciences Company Inc
M2 - Mon Jan 18, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/7rp5wx/drug_overdose) has announced the addition of the "Drug Overdose Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Drug Overdose Global Clinical Trials Review, H2, 2015" provides an overview of Drug Overdose clinical trials scenario. This report provides top line data relating to the clinical trials on Drug Overdose. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - BTG Plc - ZonMw - Smerud Medical Research International AS - Cumberland Pharmaceuticals, Inc. - AS The Norwegian Ether Factory - Altasciences Company Inc For more information visit http://www.researchandmarkets.com/research/7r...g_overdose
CPIX: 4.62 (+0.04)
Cumberland Pharmaceuticals Presentation Now Available for On-Demand Viewing
CNW Group - Mon Dec 07, 7:30AM CST
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
CPIX: 4.62 (+0.04)
Equities on the Move - Research on Select Bancorp, Cumberland Pharmaceuticals, Howard Bancorp and Atlantic Coast Financial
ACCESSWIRE - Wed Dec 02, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / December 2, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Select Bancorp Inc (NASDAQ: SLCT), Cumberland Pharmaceuticals Inc (NASDAQ: CPIX), Howard Bancorp Inc (NASDAQ: HBMD) and Atlantic Coast Financial Corp (NASDAQ: ACFC). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HBMD: 12.82 (+0.16), CPIX: 4.62 (+0.04), SLCT: 8.04 (+0.01), ACFC: 6.70 (+0.03)
NYSE, Nasdaq and OTC Companies to Present Online to Investors on December 3
CNW Group - Tue Dec 01, 2:07PM CST
VirtualInvestorsConferences.com host CEOs and senior executives: live questions answered during online roadshow and in virtual trade booths
SAN: 4.56 (+0.04), CPG: 15.38 (+0.24), CPIX: 4.62 (+0.04), IMUC: 0.12 (-0.01)
Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 3
PR Newswire - Mon Nov 30, 8:05AM CST
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
CPIX: 4.62 (+0.04)
Caldolor® Launched In Australia For Treatment Of Pain And Fever
PR Newswire - Mon Nov 23, 3:05PM CST
Cumberland Pharmaceuticals (NASDAQ: CPIX) announced today the launch of Caldolor® in Australia. Caldolor is an intravenous formulation of ibuprofen, approved by Therapeutic Goods Administration (TGA) in Australia as a new injectable, non-narcotic treatment for pain and reduction of fever in adults. It is designed primarily for patients in the hospital setting, who cannot tolerate oral medications. Caldolor is distributed in Australia by Seqirus(TM), a part of the CSL Group, under license from Cumberland Pharmaceuticals Inc. who developed and registered the product in the United States.
CPIX: 4.62 (+0.04)
(0)
(0)Scroll down for more posts ▼